These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 25850429)
1. Bevacizumab in recurrent glioblastoma: five informative patient scenarios. Mason WP Can J Neurol Sci; 2015 May; 42(3):149-56. PubMed ID: 25850429 [TBL] [Abstract][Full Text] [Related]
2. [Treatment of recurrent glioblastoma with single-agent bevacizumab]. Sinkó D; Nemeskéri C Orv Hetil; 2016 Mar; 157(13):500-3. PubMed ID: 26996897 [TBL] [Abstract][Full Text] [Related]
3. Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors. Johansen MD; Urup T; Holst CB; Christensen IJ; Grunnet K; Lassen U; Friis S; Poulsen HS Cancer Invest; 2018; 36(9-10):512-519. PubMed ID: 30727779 [TBL] [Abstract][Full Text] [Related]
4. The role of avastin in the management of recurrent glioblastoma. Sweet JA; Feinberg ML; Sherman JH Neurosurg Clin N Am; 2012 Apr; 23(2):331-41, x. PubMed ID: 22440876 [TBL] [Abstract][Full Text] [Related]
5. Clinical effectiveness of bevacizumab in patients with recurrent brain tumours: A population-based evaluation. de Lemos ML; Markarian A; Chan E; Schaff K; Walisser S J Oncol Pharm Pract; 2018 Jan; 24(1):33-36. PubMed ID: 27903792 [TBL] [Abstract][Full Text] [Related]
7. FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival. Schaub C; Greschus S; Seifert M; Waha A; Blasius E; Rasch K; Landwehr C; Mack F; Schäfer N; Stuplich M; Kebir S; Vilz B; Scheffler B; Boström J; Simon M; Urbach H; Glas M; Herrlinger U Oncology; 2013; 85(3):191-5. PubMed ID: 24008924 [TBL] [Abstract][Full Text] [Related]
8. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Cohen MH; Shen YL; Keegan P; Pazdur R Oncologist; 2009 Nov; 14(11):1131-8. PubMed ID: 19897538 [TBL] [Abstract][Full Text] [Related]
9. Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors. Narita Y Jpn J Clin Oncol; 2013 Jun; 43(6):587-95. PubMed ID: 23585688 [TBL] [Abstract][Full Text] [Related]
10. ASCO 2013: bevacizumab and glioblastoma--a marriage dissolution? Addeo R; Perri F; Parlato C; Della Vittoria G Curr Med Res Opin; 2014 Sep; 30(9):1871-3. PubMed ID: 24803042 [TBL] [Abstract][Full Text] [Related]
11. Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies. Field KM; Jordan JT; Wen PY; Rosenthal MA; Reardon DA Cancer; 2015 Apr; 121(7):997-1007. PubMed ID: 25263092 [TBL] [Abstract][Full Text] [Related]
12. Use of bevacizumab in recurrent glioblastoma. Ghiaseddin A; Peters KB CNS Oncol; 2015; 4(3):157-69. PubMed ID: 25906439 [TBL] [Abstract][Full Text] [Related]
13. [Single center experience with bevacizumab in a cohort of patients treated for a relapsing glioblastoma]. Mbagui R; Ricard D; Vallard A; Magne N; Dulou R; Lahutte M; Calcina P; Taillia H; Yordanova Y; Delmas JM; Bauduceau O; Chargari C Presse Med; 2016 May; 45(5):e131-8. PubMed ID: 26916405 [TBL] [Abstract][Full Text] [Related]
14. Assessment of tumor oxygenation and its impact on treatment response in bevacizumab-treated recurrent glioblastoma. Bonekamp D; Mouridsen K; Radbruch A; Kurz FT; Eidel O; Wick A; Schlemmer HP; Wick W; Bendszus M; Østergaard L; Kickingereder P J Cereb Blood Flow Metab; 2017 Feb; 37(2):485-494. PubMed ID: 26861817 [TBL] [Abstract][Full Text] [Related]
15. Quantitative T1 and T2 mapping in recurrent glioblastomas under bevacizumab: earlier detection of tumor progression compared to conventional MRI. Lescher S; Jurcoane A; Veit A; Bähr O; Deichmann R; Hattingen E Neuroradiology; 2015 Jan; 57(1):11-20. PubMed ID: 25287076 [TBL] [Abstract][Full Text] [Related]
16. VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma. Martini M; de Pascalis I; D'Alessandris QG; Fiorentino V; Pierconti F; Marei HE; Ricci-Vitiani L; Pallini R; Larocca LM BMC Cancer; 2018 May; 18(1):553. PubMed ID: 29747600 [TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes with bevacizumab-containing and non-bevacizumab-containing regimens in patients with recurrent glioblastoma from US community practices. Chen C; Ravelo A; Yu E; Dhanda R; Schnadig I J Neurooncol; 2015 May; 122(3):595-605. PubMed ID: 25773061 [TBL] [Abstract][Full Text] [Related]
18. ADC quantification to classify patients candidate to receive bevacizumab treatment for recurrent glioblastoma. Asenjo García B; Navarro Guirado F; Nagib Raya F; Vidal Denis M; Bravo Rodríguez F; Galán Montenegro P Acta Radiol; 2020 Mar; 61(3):404-413. PubMed ID: 31357873 [No Abstract] [Full Text] [Related]
19. Antiangiogenic therapies for glioblastoma. Arrillaga-Romany I; Norden AD CNS Oncol; 2014; 3(5):349-58. PubMed ID: 25363007 [TBL] [Abstract][Full Text] [Related]
20. The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial. Dirven L; van den Bent MJ; Bottomley A; van der Meer N; van der Holt B; Vos MJ; Walenkamp AM; Beerepoot LV; Hanse MC; Reijneveld JC; Otten A; de Vos FY; Smits M; Bromberg JE; Taal W; Taphoorn MJ; Eur J Cancer; 2015 Jul; 51(10):1321-30. PubMed ID: 25899986 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]